2242: Understanding the Genetics of Adverse Drug Reactions in Sighthounds

Grant Status: Closed

Grant Amount: $150,000
Michael H. Court, PhD; Washington State University
February 1, 2016 - July 31, 2018

Sponsor(s): Borzoi Club of America, Inc., Chow Chow Club, Inc., Saluki Health Research, Inc.

Breed(s): Greyhound, -All Dogs
Research Program Area: General Canine Health
Donate to Support this Research Program Area


Life-threatening unanticipated reactions to drugs with a narrow margin of safety (such as those used for anesthesia and to treat cancer) are a common concern for dog owners and veterinarians. However, research conducted at Washington State University has enabled development of a simple cheek swab test (the MDR1 gene test) that is now being used by veterinarians to identify dogs that should either avoid or have reduced doses of certain drugs used to treat cancer and parasite infections. Using a similar strategy the investigators have been conducting research to identify the cause of extremely slow recovery from anesthesia (up to several days) in a high proportion of greyhounds, and also in other sighthound breed dogs (such as Scottish deerhound, Borzoi, Whippets, etc.). The investigators have recently discovered a mutation in a gene that is known to be essential for metabolism (breaking down) many commonly used anesthetic drugs (such as propofol), as well as many other drugs used in dogs. Interestingly in addition to sighthound breeds, this gene mutation is also found in some other breeds such as Border Collies. The purpose of this research project is to prove that this mutation can cause decreased drug metabolism, while also determining which drugs and which dog breeds are likely to be most impacted. The ultimate goal of this study is to develop a genetic test that could be used by veterinarians to guide the safe use of these drugs in dogs with the gene mutation.


Martinez SE, Pandey AV, Perez Jimenez TE, Zhu Z, Court MH (2024) Pharmacogenomics of poor drug metabolism in greyhounds: Canine P450 oxidoreductase genetic variation, breed heterogeneity, and functional characterization. PLoS ONE 19(2): e0297191. https://doi.org/10.1371/journal.pone.0297191

Martinez, S. E., Pandey, A. V., & Court, M. H. (2019). Isoform-Dependent Effects of Cytochrome P450 Oxidoreductase Polymorphisms on Drug Metabolism by Cytochrome P450 Enzymes in Dogs. The FASEB Journal, 33(1_supplement), 506.9-506.9. https://doi.org/10.1096/fasebj.2019.33.1_supplement.506.9

Martinez, S. E., Shi, J., Zhu, H.-J., Jimenez, T. E. P., Zhu, Z., & Court, M. H. (2019). Absolute quantitation of drug metabolizing cytochrome P450 enzymes and accessory proteins in dog liver microsomes using label-free standard-free analysis reveals inter-breed variability. Drug Metabolism and Disposition, dmd.119.088070. https://doi.org/10.1124/dmd.119.088070

Martinez, S. E., Andresen, M. C., Zhu, Z., Papageorgiou, I., & Court, M. H. (2020). Pharmacogenomics of poor drug metabolism in Greyhounds: Cytochrome P450 (CYP) 2B11 genetic variation, breed distribution, and functional characterization. Scientific Reports, 10(69). doi:10.1038/s41598-019-56660-z

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.